TURKISH JOURNAL OF ONCOLOGY 1996 , Vol 11 , Num 3
CISPLATINUM, FLUOROURACIL, AND FOLINIC ACID COMBINATION THERAPY FOR THE METASTATIC BREAST CANCER
PINAR SAİP, ERKAN TOPUZ, ADNAN AYDINER, TAFLAN SALEPÇİ, SEVİL İNANÇ, FARUK TAŞ, CUMHUR DEMİR
İ.Ü. Onkoloji Enstitüsü Tıbbi Onkoloji Bilim Dalı Twenty-one heavily pretreated antracycline resistant metastatic breast cancer patients were treated with cisplatinum 75 mg/ spm/infusion on day one, folinic acid 100 mg/ spm, fluorouracil 600 mg/ spm/IV on days one and two every 4 weeks. Patient characteristics were median age; 55 (25-64), menopausal status; 14 post-6 pre-1 perimenapausal. The metastatic sites were: 6/21 liver, 8/21 bone, 11/21 lung/pleura, 1/21 brain, 2/21 soft tissue/skip. Because 2 patients with grade III emesis could not tolerate chemotherapy after the first cycle 19 patients were evaluated for response. Three patients (16%) achieved partial response, 10 (53%) had stable disease and 6 (31 %) progressive disease. The patients received a total of 83 cycles of chemotherapy. Major acute toxicity was grade (gr) 3 emesis (5/83) 6%, the others were; gr II emesis 50/83 (60%), gr II leukopenia 5/83 (11%), gr III anemia 1/83 (1%), gr II anemia 3/83 (4%), gr II nefrotoxicity 1/83 (1%). Although this combination regimen was tolerable, it did not seem to be effective in antracycline-resistant breast cancer. Keywords :